Privia Health Group, Inc.
HealthcareNASDAQ:PRVA · NASDAQ Global Select
+$0.07 today
Vol 0.91M · Avg 0.93M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
3.1%
avg -1.4%
ROIC
2.9%
avg -1.2%
ROA
1.7%
avg -1.5%
Analysis
ROE is currently the strongest return metric at 3.1% versus its period average of -1.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Parth Mehrotra | Chief Executive Officer & Director | $1.88M | — | 47 | $434,357.00 | 0.34% |
David Mountcastle | Executive VP & CFO | $873,575.00 | — | 56 | $50,775.00 | 0.04% |
Edward Christopher Fargis | Executive Vice President, General Counsel, Chief Legal Officer & Corporate Secretary | $747,075.00 | — | 61 | $111,979.00 | 0.09% |
Robert Borchert | Senior Vice President of Investor Relations & Corporation Communications | — | — | — | — | — |
Sarath Degala | Chief Operations Officer | — | — | — | — | — |
Dana Fields | Chief Audit & Compliance Officer | — | — | — | — | — |
Jenny Harding | Chief People Officer | — | — | — | — | — |
Keith Fernandez | Executive Vice President & Chief Clinical Officer | — | — | — | — | — |
Eric J. Beyer | Executive Vice President of Medical Groups | — | — | — | — | — |
Konda Mullapudi | Executive Vice President & Chief Technology Officer | — | — | — | — | — |
Jay Stevens | Senior Vice President & Chief Growth Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$10.05M
Net Sentiment
$10.05M
Net selling
Most Active
Mountcastle David
12 transactions
1–10 of 29
Analysis
Insiders reported 0 buys worth $0.00 and 29 sells worth $10.05M over the last 12 months. That adds up to net selling of $10.05M. Mountcastle David was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.9% | +12.3% (8yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.9% over three years. Forward estimates point to Revenue at +12.3% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Envista Holdings Corp
NYSE:NVST
$4.00B
ICU Medical, Inc.
NASDAQ:ICUI
$3.55B
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
$3.05B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Premier, Inc.
PINC
$2.34B
Prestige Consumer Healthcare Inc.
NYSE:PBH
$2.27B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
Who manages PRVA?
Privia Health Group, Inc. (PRVA) lists 11 active executives. The top listed executive is Parth Mehrotra, Chief Executive Officer & Director.
Are PRVA insiders buying or selling?
Recent insider activity shows net selling of $18.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.